task_path stringlengths 3 199 ⌀ | dataset stringlengths 1 128 ⌀ | model_name stringlengths 1 223 ⌀ | paper_url stringlengths 21 601 ⌀ | metric_name stringlengths 1 50 ⌀ | metric_value stringlengths 1 9.22k ⌀ |
|---|---|---|---|---|---|
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2D6_Substrate_CarbonMangels | 0.574 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.CYP3A4_Substrate_CarbonMangels | 0.576 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2C9_Substrate_CarbonMangels | 0.375 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.Half_Life_Obach | 0.085 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.Clearance_Microsome_AZ | 0.365 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.Clearance_Hepatocyte_AZ | 0.289 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.hERG | 0.825 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.AMES | 0.814 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.DILI | 0.886 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.LD50_Zhu | 0.678 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.Solubility_AqSolDB | 1.026 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.Caco2_Wang | 0.546 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.HIA_Hou | 0.978 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.Pgp_Broccatelli | 0.929 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.Bioavailability_Ma | 0.577 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.Lipophilicity_AstraZeneca | 0.547 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.BBB_Martins | 0.892 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.PPBR_AZ | 10.075 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.VDss_Lombardo | 0.559 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2D6_Inhibition_Veith | 0.721 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.CYP3A4_Inhibition_Veith | 0.902 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2C9_Inhibition_Veith | 0.829 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2D6_Substrate_CarbonMangels | 0.704 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.CYP3A4_Substrate_CarbonMangels | 0.582 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2C9_Substrate_CarbonMangels | 0.381 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.Half_Life_Obach | 0.151 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.Clearance_Microsome_AZ | 0.585 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.Clearance_Hepatocyte_AZ | 0.413 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.hERG | 0.778 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.AMES | 0.842 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.DILI | 0.919 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttrMasking | https://arxiv.org/abs/2102.09548v2 | TDC.LD50_Zhu | 0.685 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.Solubility_AqSolDB | 0.907 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.Caco2_Wang | 0.599 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.HIA_Hou | 0.936 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.Pgp_Broccatelli | 0.895 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.Bioavailability_Ma | 0.566 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.Lipophilicity_AstraZeneca | 0.541 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.BBB_Martins | 0.842 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.PPBR_AZ | 10.194 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.VDss_Lombardo | 0.457 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2D6_Inhibition_Veith | 0.616 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.CYP3A4_Inhibition_Veith | 0.840 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2C9_Inhibition_Veith | 0.735 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2D6_Substrate_CarbonMangels | 0.617 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.CYP3A4_Substrate_CarbonMangels | 0.590 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2C9_Substrate_CarbonMangels | 0.344 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.Half_Life_Obach | 0.239 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.Clearance_Microsome_AZ | 0.532 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.Clearance_Hepatocyte_AZ | 0.366 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.hERG | 0.738 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.AMES | 0.818 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.DILI | 0.859 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | GCN | https://arxiv.org/abs/2102.09548v2 | TDC.LD50_Zhu | 0.649 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | Galactica-GAL-120B | https://arxiv.org/abs/2211.09085v1 | TDC.BBB_Martins | 0.661 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | Galactica-GAL-1.3B | https://arxiv.org/abs/2211.09085v1 | TDC.BBB_Martins | 0.604 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | Galactica-GAL-30B | https://arxiv.org/abs/2211.09085v1 | TDC.BBB_Martins | 0.596 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | Galactica-GAL-6.7B | https://arxiv.org/abs/2211.09085v1 | TDC.BBB_Martins | 0.535 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | Galactica-GAL-125M | https://arxiv.org/abs/2211.09085v1 | TDC.BBB_Martins | 0.393 |
Semantic Communication | Europarl | Euro Parl | https://arxiv.org/abs/2006.10685v3 | 0..5sec | 1 |
Code Completion | Defects4J | Rambo | https://arxiv.org/abs/2409.15204v2 | Compilation Rate | 76.47 |
Code Completion | Defects4J | Rambo | https://arxiv.org/abs/2409.15204v2 | Pass@1 | 63.73 |
Code Completion | Defects4J | Rambo | https://arxiv.org/abs/2409.15204v2 | BLEU | 66.29 |
Code Completion | Defects4J | RepoCoder | https://arxiv.org/abs/2303.12570v3 | Compilation Rate | 74.02 |
Code Completion | Defects4J | RepoCoder | https://arxiv.org/abs/2303.12570v3 | Pass@1 | 59.8 |
Code Completion | Defects4J | RepoCoder | https://arxiv.org/abs/2303.12570v3 | BLEU | 63.52 |
Code Completion | CodeXGLUE - Github Java Corpus | CodeGPT-adapted | https://arxiv.org/abs/2102.04664v2 | Accuracy (token-level) | 77.13 |
Code Completion | CodeXGLUE - Github Java Corpus | CodeGPT-adapted | https://arxiv.org/abs/2102.04664v2 | EM (line-level) | 26.43 |
Code Completion | CodeXGLUE - Github Java Corpus | CodeGPT-adapted | https://arxiv.org/abs/2102.04664v2 | Edit Sim (line-level) | 63.03 |
Code Completion | CodeXGLUE - Github Java Corpus | CodeT5+ 770M | https://arxiv.org/abs/2305.07922v2 | EM (line-level) | 37.90 |
Code Completion | CodeXGLUE - Github Java Corpus | CodeT5+ 770M | https://arxiv.org/abs/2305.07922v2 | Edit Sim (line-level) | 72.25 |
Code Completion | CodeXGLUE - Github Java Corpus | CodeT5+ 220M | https://arxiv.org/abs/2305.07922v2 | EM (line-level) | 35.17 |
Code Completion | CodeXGLUE - Github Java Corpus | CodeT5+ 220M | https://arxiv.org/abs/2305.07922v2 | Edit Sim (line-level) | 69.48 |
Code Completion | CodeXGLUE - PY150 | CodeGPT-adapted | https://arxiv.org/abs/2102.04664v2 | Accuracy (token-level) | 75.11 |
Code Completion | CodeXGLUE - PY150 | CodeGPT-adapted | https://arxiv.org/abs/2102.04664v2 | EM (line-level) | 39.65 |
Code Completion | CodeXGLUE - PY150 | CodeGPT-adapted | https://arxiv.org/abs/2102.04664v2 | Edit Sim (line-level) | 69.84 |
Code Completion | CodeXGLUE - PY150 | CodeT5+ 770M | https://arxiv.org/abs/2305.07922v2 | EM (line-level) | 44.86 |
Code Completion | CodeXGLUE - PY150 | CodeT5+ 770M | https://arxiv.org/abs/2305.07922v2 | Edit Sim (line-level) | 74.22 |
Code Completion | CodeXGLUE - PY150 | CodeT5+ 220M | https://arxiv.org/abs/2305.07922v2 | EM (line-level) | 43.42 |
Code Completion | CodeXGLUE - PY150 | CodeT5+ 220M | https://arxiv.org/abs/2305.07922v2 | Edit Sim (line-level) | 73.69 |
Code Completion | Rambo Benchmark | Rambo | https://arxiv.org/abs/2409.15204v2 | Compilation Rate | 61.70 |
Code Completion | Rambo Benchmark | Rambo | https://arxiv.org/abs/2409.15204v2 | BLEU | 50.44 |
Code Completion | Rambo Benchmark | RepoCoder | https://arxiv.org/abs/2303.12570v3 | Compilation Rate | 58.09 |
Code Completion | Rambo Benchmark | RepoCoder | https://arxiv.org/abs/2303.12570v3 | BLEU | 46.22 |
Code Completion | DotPrompts | SantaCoder-MGD | https://arxiv.org/abs/2306.10763v2 | Compilation Rate | 73.03 |
Code Completion | DotPrompts | SantaCoder | null | Compilation Rate | 59.97 |
Code Completion | DotPrompts | SantaCoder | https://arxiv.org/abs/2306.10763v2 | Compilation Rate | 59.79 |
Code Completion | SAFIM | deepseek-coder-33b-base | https://arxiv.org/abs/2403.04814v3 | Algorithmic | 60.78 |
Code Completion | SAFIM | deepseek-coder-33b-base | https://arxiv.org/abs/2403.04814v3 | Average | 69.01 |
Code Completion | SAFIM | deepseek-coder-33b-base | https://arxiv.org/abs/2403.04814v3 | Control | 71.10 |
Code Completion | SAFIM | deepseek-coder-33b-base | https://arxiv.org/abs/2403.04814v3 | API | 75.16 |
Code Completion | SAFIM | deepseek-coder-6.7b-base | https://arxiv.org/abs/2403.04814v3 | Algorithmic | 54.74 |
Code Completion | SAFIM | deepseek-coder-6.7b-base | https://arxiv.org/abs/2403.04814v3 | Average | 63.40 |
Code Completion | SAFIM | deepseek-coder-6.7b-base | https://arxiv.org/abs/2403.04814v3 | Control | 65.79 |
Code Completion | SAFIM | deepseek-coder-6.7b-base | https://arxiv.org/abs/2403.04814v3 | API | 69.68 |
Code Completion | SAFIM | starcoderbase | https://arxiv.org/abs/2403.04814v3 | Algorithmic | 44.11 |
Code Completion | SAFIM | starcoderbase | https://arxiv.org/abs/2403.04814v3 | Average | 55.54 |
Code Completion | SAFIM | starcoderbase | https://arxiv.org/abs/2403.04814v3 | Control | 54.46 |
Code Completion | SAFIM | starcoderbase | https://arxiv.org/abs/2403.04814v3 | API | 68.06 |
Code Completion | SAFIM | gpt-4-1106-preview | https://arxiv.org/abs/2403.04814v3 | Algorithmic | 42.11 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.